Next, to test whether reducing FOSB levels in advanced SCD inhibitor–treated tumors (when they presumably start acquiring resistance to the inhibitor) exerted any effect on tumor growth and survival, we performed an additional experiment. The gene discussed is SCD; the disease is neoplasm.